Hsbc Holdings PLC decreased its stake in Cencora, Inc. (NYSE:COR – Free Report) by 15.7% in the fourth quarter, HoldingsChannel reports. The firm owned 394,058 shares of the company’s stock after selling 73,629 shares during the period. Hsbc Holdings PLC’s holdings in Cencora were worth $133,240,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of COR. T. Rowe Price Investment Management Inc. raised its holdings in Cencora by 160.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock worth $2,262,956,000 after buying an additional 4,123,795 shares during the period. Norges Bank acquired a new position in shares of Cencora in the fourth quarter worth about $822,506,000. Marshall Wace LLP boosted its holdings in shares of Cencora by 518.9% in the third quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock worth $623,534,000 after buying an additional 1,672,762 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Cencora by 528.9% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock worth $461,250,000 after acquiring an additional 1,241,186 shares in the last quarter. Finally, Viking Global Investors LP raised its holdings in shares of Cencora by 95.0% during the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after acquiring an additional 1,013,913 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.
Cencora Stock Performance
COR stock opened at $271.99 on Monday. The firm has a 50 day simple moving average of $284.59 and a 200 day simple moving average of $324.10. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The stock has a market cap of $52.92 billion, a P/E ratio of 20.86, a P/E/G ratio of 1.47 and a beta of 0.59. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95.
Cencora announced that its board has initiated a share repurchase plan on Thursday, May 21st that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to reacquire up to 3.9% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s management believes its shares are undervalued.
Cencora Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were paid a $0.60 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. Cencora’s dividend payout ratio is 18.40%.
Analysts Set New Price Targets
Several equities research analysts recently commented on the stock. Leerink Partners restated an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Barclays lowered their price objective on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 10th. UBS Group increased their target price on Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Citigroup decreased their target price on Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Robert W. Baird lowered their price target on Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Twelve analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $374.00.
Read Our Latest Stock Report on COR
Cencora Company Profile
Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.
Read More
- Five stocks we like better than Cencora
- 3 Inflation-Fighting Stocks Built for Higher Oil Prices
- 3 Biotech Firms With Major Potential Catalysts in the Coming Months
- Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally?
- 3 Small-Cap Stocks Getting a Russell 2000 Rebalance Boost
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
